Natco Pharma Ltd

Natco Pharma Earnings Call: Key Takeaways

Natco Pharma reported FY26 revenue of INR 43,759 Mn and PAT of INR 14,185 Mn, driven by US generic launches and high export formulation contributions.

Natco Pharma Q4 FY26 Results: Net Profit ₹269 Cr, Down 33.7% YoY

Natco Pharma Ltd reported revenue from operations of ₹739.1 Cr (-39.5% YoY) and net profit of ₹269 Cr (-33.7% YoY) for Q4 FY26.

Key figure

Net profit ₹269 Cr · -33.7% YoY

Natco Pharma Financial Results

Natco Pharma approved audited FY26 financial results, reporting consolidated total revenue of ₹4,375.9 Crore. The Board also amended CSR and fair disclosure policies.

Natco Pharma Board Meeting Date

Natco Pharma scheduled a board meeting for May 29, 2026, to approve fiscal year financial results. The trading window remains closed for designated persons.

Natco Pharma Legal & Regulatory

Natco Pharma received a ₹4.92 Crore demand notice from NPPA for alleged overcharging on two drugs. The company reports no material impact on its operations.

Value

₹4.92 Cr

Natco Pharma Other Announcement

Natco Pharma Limited submitted its compliance certificate under Regulation 74(5) of SEBI (DP) Regulations for the quarter ended March 31, 2026. The registrar confirmed that securities received for dematerialization were processed and the depositories' records updated within 15 days.